Related Experiment Video
Updated: Nov 3, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury
Ramiro Palazón-García1, Ana María Benavente-Valdepeñas2
1Physical Medicine and Rehabilitation Department, Hospital Nacional de Parapléjicos, 45004 Toledo, Spain.
Botulinum toxin, a potent neurotoxin, is increasingly used to treat spasticity. This review details its historical development and application in managing spinal cord injury spasticity.
Area of Science:
- Neuroscience
- Pharmacology
- Medical History
Background:
- Botulinum toxin, known for centuries, is one of the most potent neurotoxins.
- Medical applications, particularly for spasticity, emerged in the 20th century.
- It is the sole recommended pharmacological treatment for stroke and cerebral palsy spasticity.
Purpose of the Study:
- To review the historical advancements in the therapeutic use of botulinum toxin.
- To specifically examine its application in treating spasticity associated with spinal cord injuries.
Main Methods:
- Historical literature review.
- Analysis of scientific publications on botulinum toxin.
- Examination of clinical applications and research.
Main Results:
- Botulinum toxin has evolved from a potent toxin to a valuable therapeutic agent.
- Its efficacy in treating spasticity from stroke and cerebral palsy is well-established.
- Despite lacking approval, botulinum toxin is utilized as an adjuvant therapy for spinal cord injury spasticity.
Conclusions:
- The historical trajectory of botulinum toxin demonstrates significant therapeutic evolution.
- Botulinum toxin shows promise and is being explored for spinal cord injury spasticity management.
- Further research and approval are needed for its widespread use in spinal cord injuries.
More Related Videos
10:49Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
08:40Isokinetic Robotic Device to Improve Test-Retest and Inter-Rater Reliability for Stretch Reflex Measurements in Stroke Patients with Spasticity
Published on: June 12, 2019
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Skeletal Muscle Relaxants: Therapeutic Uses
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...